Ascendis Pharma AS (ASND NASDAQ) stock market data APIs
$175.6582
1.75(1%)
as of July 11, 2025
Try our APIs with
free plan!
Ascendis Pharma AS Financial Data Overview
Price chart is built with
Anychart
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Denmark, rest of Europe, North America, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark.
Prev. Close
175.6582
Open
177.4115
High
175.4786
Low
172.1186
52 wk Range
111.09-183
Market Cap
10 584 M
Shares Outstanding
60 494 K
Revenue
369 M
EPS
-1.58
Beta
0.361
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Ascendis Pharma AS data using free add-ons & libraries
Get Ascendis Pharma AS Fundamental Data
Ascendis Pharma AS Fundamental data includes:
- Net Revenue: 369 M
- EBITDA: -328 827 008
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-04-30
- EPS/Forecast: -1.5055
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Ascendis Pharma AS News
New
New 3-Year Phase 3 Data Confirmed Sustained Response to TransCon® PTH (Palopegteriparatide) Therapy in Adults with Hypoparathyroidism, Including Improvements in Biochemistries, Kidney Function, and Quality of Life
COPENHAGEN, Denmark, July 14, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced new data from Week 156 of its Phase 3 PaTHway Trial confirming that long-term treatment with...
European Equities Traded in the US as ADRs Edge Up in Monday Trading
European equities traded in the US as American depositary receipts edged up Monday with the S&P Euro PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscri...
Exploring 3 High Growth Tech Stocks In The US Market
Over the last 7 days, the United States market has remained flat, yet it is up 11% over the past year with earnings anticipated to grow by 15% per annum in the coming years. In this context, identifyi...
Exploring 3 High Growth Tech Stocks In The US Market
The U.S. market is currently experiencing a mix of volatility and optimism, with investor sentiment being influenced by renewed tariff threats and record highs in major indices like the S&P 500 and Na...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
